ArticleAsian Pacific journal of cancer prevention : APJCP2026
In Vitro Anticancer Activity of Green-Synthesized Zinc Oxide Nanoparticles from Root Extract of Sida schimperiana against MDA-MB-231 Breast Cancer Cell Lines.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis work addressed the fact that nano phytoformulations have emerged as promising, biocompatible alternatives to conventional cancer drugs, helping to overcome drug resistance in cancer and offering sustainable, biocompatible, and effective drug delivery. This study aimed to synthesize zinc oxide nanoparticles (SS-ZnO NPs) using an eco-friendly green synthesis method from Sida schimperiana aqueous root extract (SS-AQ), and to evaluate their selective cytotoxicity against MDA-MB-231 breast cancer cells.
methodsThe SS-ZnO NPs were characterized using spectroscopic (FTIR, XRD, DLS), microscopic (SEM, TEM), and chemical (EDX) analytical techniques. The selective cytotoxicity of SS-ZnO NPs against breast cancer cell lines (MDA-MB-231) and normal cell lines (L929) was evaluated using the MTT assay.
resultsXRD analysis confirmed that SS-ZnO NPs possess a crystalline, hexagonal wurtzite structure with an average size of 55.4 nm. DLS analysis indicated that the SS-ZnO NPs are monodispersed with a negative surface charge of -28.9 mV, suggesting high colloidal stability. SEM and TEM-EDX analyses revealed that the SS-ZnO NPs exhibit a pseudo-spherical, rough morphology with an average particle size of 22.65 nm. Strong absorption peaks at 1.01 keV and 0.52 keV were observed, corresponding to the characteristic signals of Zn and oxygen, respectively. The MTT assay demonstrated that SS-ZnO NPs exhibited significant, dose-dependent selective cytotoxicity against MDA-MB-231 breast cancer cell lines, with inhibition ranging from 10.14% to 62.44% at concentrations of 6.25-100 µg/mL, and an IC₅₀ value of 45.28 µg/mL (p ≤ 0.01). In comparison, SS-AQ exhibited 8.81% to 58.11% inhibition at the same concentration range, with an IC₅₀ of 50.16 µg/mL (p ≤ 0.01).
conclusionThe findings of the current study highlight that bio-inspired SS-ZnO NPs possess enhanced anticancer properties and can be considered a promising anticancer agent with potent, specific cytotoxic efficacy against MDA-MB-231 breast cancer cells, offering a potential alternative nanotherapeutic approach with reduced toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.